One Size Does Not Fit All: Using Population Pharmacokinetics for Tailored Hemophilia Care

In order to prevent and treat bleeding in patients with hemophilia A, the activity of the replaced clotting factor VIII must reach or exceed a target level over a period of time. Pharmacokinetic (PK) measures are therefore used to determine the dosing regiment of different factor VIII replacement products. Recently, extended half-life recombinant factor VIII products with improved PK profiles have been approved and these reduce treatment burden and improve treatment adherence.

In this CME Outfitters live and on-demand webcast, renowned hematologists will discuss the clinical significance of the results of the head-to-head comparison study of PK profiles of extended half-life factor VIII products including the application of population PK models and shared decision-making to provide personalized hemophilia A therapy.

At the end of this CE activity, participants should be able to:
-Summarize the comparative PK data and the clinical significance of popPK studies on factor VIII replacement therapies.
-Apply popPK models to determine individualized dosing regiments for patients with hemophilia A.
-Integrate approaches for SDM to develop patient-centered, PK-based treatment plans for patients with hemophilia A.

The following learning objectives pertain only to those requesting CNE or CPE credit:
-Summarize the comparative PK data and the clinical significance of popPK studies on factor VIII replacement therapies.
-Explain popPK models that can determine individualized dosing regimens for patients with hemophilia A.
-Describe approaches for SDM to develop patient-centered, PK-based treatment plans for patients with hemophilia A.